DaVita Inc. (DVA) Revenue by Segment
DaVita revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), DaVita's largest business segment was U. S. Dialysis and Related Lab Services, with $3.00 billion or 84% of revenue, up 3.6% from a year earlier. Next: All other segments (16%).
By product or service, Medicare and Medicare Advantage brought in 49%, Commercial Payors brought in 26% and All other segments brought in 16% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was All other segments (+14.7%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
DaVita Inc.
Revenue breakdown
Fiscal quarters, from company filings
DaVita revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| U. S. Dialysis and Related Lab Services | $3.0B | $2.9B | $3.0B | $2.9B | 84% |
| All other segments | $553.6M | $494.3M | $452.1M | $482.9M | 16% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
DaVita revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Medicare and Medicare Advantage | $1.7B | $1.7B | $1.7B | $1.7B | 49% |
| Commercial Payors | $940.2M | $954.2M | $956.9M | $947.0M | 26% |
| All other segments | $553.6M | $494.3M | $452.1M | $482.9M | 16% |
| Medicaid and Managed Medicaid | $226.9M | $212.8M | $214.7M | $217.7M | 6% |
| Other Government Payors | $88.8M | $92.9M | $87.0M | $83.1M | 2% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are DaVita's business segments?
U. S. Dialysis and Related Lab Services and All other segments (as reported for Q2 fiscal 2026).
Which business segment makes the most money for DaVita?
U. S. Dialysis and Related Lab Services: $3.00 billion, or 84% of revenue, in Q2 fiscal 2026.
What are DaVita's main products and services?
By revenue in Q2 fiscal 2026: Medicare and Medicare Advantage (49%), Commercial Payors (26%), All other segments (16%) and Medicaid and Managed Medicaid (6%).
